Therefore, current pharmacotherapeutic strategies have focused on inhibiting the production of Ang II (ACE inhibitors and direct renin inhibitors) or AT1R blockade [angiotensin receptor blockers (ARBs)] to delay the progression of renal diseases [4]. This evidence concerns the gene ACE and kidney disorder.